Compounded MOTS-c

No — and we want to be straight about that. Most of the published MOTS-c research is preclinical, conducted in rodent and cell models, where it activates AMPK and improves metabolic markers. Human research is emerging: circulating MOTS-c rises after endurance exercise, and it has entered early clinical investigation, but its metabolic benefits are not established in people. MOTS-c should be viewed as an experimental, research-stage peptide, not a proven treatment.

In preclinical studies, MOTS-c may support glucose metabolism, insulin sensitivity, exercise capacity, and healthy-aging markers, largely by activating the AMPK energy-sensing pathway. It is sometimes called an “exercise-mimetic” because some of its effects overlap with the metabolic signals triggered by physical activity. These are research findings, not guaranteed outcomes.

Sermorelin works on the growth hormone axis via the pituitary. MOTS-c is in a different category entirely — a mitochondrial-derived peptide that signals through cellular energy pathways like AMPK rather than hormones. They target different systems, and a clinician can advise whether either fits your goals.

MOTS-c is given as a subcutaneous injection, typically 2–3 times per week, with many protocols running in cycles of several weeks on followed by a break. There is no FDA-established dosing schedule, so your prescribing doctor sets a regimen based on your goals and labs.

Yes. Baseline metabolic labs (fasting glucose, HbA1c, lipid panel, and others as indicated) are reviewed by your prescribing doctor before a prescription is issued. If you have recent labs, you can upload them; otherwise we coordinate at-home or in-network draws, then recheck to monitor your response.

Reported effects are generally mild — injection-site reactions, transient fatigue or flushing, headache, or changes in appetite. Because long-term human safety data are limited, monitoring matters, and you should report any unexpected or persistent symptoms to your care team. Combining MOTS-c with glucose-lowering medication should be supervised due to hypoglycemia risk.

Peptide12 partners with state-licensed compounding pharmacies that hold state and federal licensure and undergo regular USP <797> sterility audits. Every batch is third-party tested for identity, potency, sterility, and endotoxin before release. Compounded MOTS-c is not FDA-approved as a finished drug product but is prepared from regulated active ingredients under individualized prescription.

Compounded medications are typically not covered by commercial insurance. Many patients use HSA or FSA funds. Your care team can help you check eligibility and walk you through reimbursement documentation if needed.

MOTS-c is studied for metabolic health rather than marketed as a weight-loss drug, and preclinical work showed reduced diet-induced obesity in mice. There is no proven weight-loss effect in humans, so it is best explored as one part of a broader, doctor-supervised metabolic protocol — not a standalone fat-loss solution.